Loading patent…
AssigneesTechnische Universitä Dresden, Centre National de la Recherche Scientifique (CNRS), Universite' D'Ais-Marseille, Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsMichael SIEWEKE, ClaraJana Lui ELENDNER, Jeremy FAVRET, Sandrine SARAZIN, Lahmar QODS
Estimating the term…
The present invention relates to a human macrophage for use in cancer therapy, said human macrophage comprising at least one mutation in both alleles of a chromosomal gene, wherein said macrophage is resistant to tumor-induced reprogramming and/or shows anti-tumor activity. The human macrophage of the invention demonstrates typical markers of an M1 macrophage, such as the presence of MHC class II proteins, even after having been cultured in an environment which promotes M2-polarization, such as in the presence of M-CSF and/or IL4 and/or IL13. The invention also relates to a collection of human macrophages of the invention, to their use in medicine, and in particular to their use in cancer therapy such as the treatment of solid tumors as a preferred example.
A human macrophage comprising at least one mutation in both alleles of a gene located on a chromosome, wherein the human macrophage is resistant to M-CSF induced M2-polarization for use in the treatment of cancer.
A human induced pluripotent stem cell or human embryonic stem cell comprising at least one mutation in both alleles of a gene located on a chromosome, wherein the gene is selected from the group consisting of STAT6, IRF4, PPARg, MAFB, MAF, KLF4, C/EPBb, GATA3, JMJD3, SOCS2, SOCS1, TMEM106A and AKT1, and wherein the mutation is a deletion.
Dependencies are inferred from the claim text.